Bone disease in patients with Gaucher disease

References

• Grabowski GA, Petsko GA, Kolodny E. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. On line metabolic and molecular basis of inherited disease (Chapter 146). McGraw-Hill; NY, USA: 2010
   Google Scholar
• Fuller M, Rozaklis T, Lovejoy M, et al. Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease. Mol Genet Metab 2008;93:437-43
   PubMedGoogle Scholar
• Elleder M. Glucosylceramide transfer from lysosomes – the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J Inherit Metab Dis 2006;29:707-15
   PubMed Web of Science ®Google Scholar
• Human genome mutation database. 2013. Available from: www.hgmd.cf.ac.uk
   Google Scholar
• Fairley C, Zimran A, Phillips M, et al. Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. J Inherit Metab Dis 2008;31:738-44
   PubMed Web of Science ®Google Scholar
• Mistry PK, Deegan P, Vellodi A, et al. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 2009;147:561-70
   PubMed Web of Science ®Google Scholar
• Tylki-Szymañska A, Keddache M, Grabowski GA. Characterization of neuronopathic Gaucher disease among ethnic Poles. Genet Med 2006;8:8-15
   PubMed Web of Science ®Google Scholar
• Mikosch P, Hughes D. An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr 2010;160:609-24
   PubMedGoogle Scholar
• Mikosch P. Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone. Best Pract Res Clin Rheumatol 2011;25:665-81
   PubMedGoogle Scholar
• Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;169:2835-42
   Google Scholar
• Doneda D, Netto CB, Moulin CC, et al. Effects of imiglucerase on the growth and metabolism of Gaucher disease type 1 patients: a systematic review. Nutr Metab (Lond) 2013;10:34
   PubMed Web of Science ®Google Scholar
• Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy/or enzyme replacement. Isr Med Assoc J 2000;2:158-63
   PubMed Web of Science ®Google Scholar
• Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-8
   PubMed Web of Science ®Google Scholar
• Misty PK, Weinreb NJ, Kaplan P, et al. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis 2011;46:66-72
   PubMedGoogle Scholar
• Ciana G, Deroma L, Franzil AM, et al. Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients. J Inherit Metab Dis 2012;35:1101-6
   PubMedGoogle Scholar
• Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005;105:4569-72
   PubMed Web of Science ®Google Scholar
• Deegan PB, Pavlova E, Tindall J, et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Blood Cells Mol Dis 2011;46:27-33
   PubMedGoogle Scholar
• Drelichman G, Linares A, Villalobos J, et al. Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease. Medicina (B Aires) 2012;72:273-82
   PubMedGoogle Scholar
• Poll LW, Maas M, Terk MR, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 2002;75(Suppl 1):A25-36
   PubMedGoogle Scholar
• Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging – initial experience. Radiology 2003;229:554-61
   PubMed Web of Science ®Google Scholar
• Roca M, Mota J, Alfonso P, et al. S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease. Eur J Radiol 2007;62:132-7
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Cappellini MD, Cox TM, et al. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med 2010;12:44-51
   PubMed Web of Science ®Google Scholar
• Kallish S, Kaplan P. A disease severity scoring system for children with type 1 Gaucher disease. Eur J Pediatr 2013;172:39-43
   PubMed Web of Science ®Google Scholar
• Erba PA, Minichilli F, Giona F, et al. 99mTc-sestamibi scintigraphy to monitor the long-term efficacy of enzyme replacement therapy on bone marrow infiltration in patients with Gaucher disease. J Nucl Med 2013;54:1717-24
   PubMedGoogle Scholar
• Yeh M, Weinreb NJ, Deegan P, et al. Avascular necrosis in untreated patients with type 1 Gaucher disease. Molec Genet Metab 2009;98:62
   Google Scholar
• Weinreb NJ, Goldblatt J, Villalobos J, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 2013;36:543-53
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-9
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am J Med 2002;113:112-19
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Barranger J, Packman S, et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 2007;6:675-588
   Google Scholar
• Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone density by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 2008;73:430-44
   PubMed Web of Science ®Google Scholar
• Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996;129:149-53
   PubMed Web of Science ®Google Scholar
• Andersson HC, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008;6:1182-90
   Google Scholar
• Maas M, Hangartner T, Mariani G, et al. Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Skeletal Radiol 2008;37:185-8
   PubMed Web of Science ®Google Scholar
• Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucease on BMD in type 1 Gaucher disease. J Bone Miner Res 2007;22:119-26
   PubMed Web of Science ®Google Scholar
• Brumshtein B, Salinas P, Peterson B, et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010;20:24-32
   PubMed Web of Science ®Google Scholar
• Morris JL. Velaglucerase alfa for the management of type 1 Gaucher disease. Clin Ther 2012;34:259-71
   PubMed Web of Science ®Google Scholar
• Hollak CE. An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease. Core Evid 2012;7:15-20
   PubMedGoogle Scholar
• van Dussen L, Cox TM, Hendriks EJ, et al. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. Haematologica 2012;97:1850-4
   PubMedGoogle Scholar
• van Dussen L, Zimran A, Akkerman EM, et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2013;50:206-11
   PubMedGoogle Scholar
• Elstein D, Foldes AJ, Zahrieh D, et al. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol Dis 2011;47:56-61
   PubMed Web of Science ®Google Scholar
• Pastores GM, Giraldo P, Chérin P, Mehta A. Goal-oriented therapy with miglustat in Gaucher disease. Curr Med Res Opin 2009;25:23-37
   PubMed Web of Science ®Google Scholar
• Pastores GM, Elstein D, Hrebicek M, Zimran A. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther 2007;29:1645-54
   PubMed Web of Science ®Google Scholar
• Hollak CE, Hughes D, van Schaik IN, et al. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 2009;18:770-7
   PubMed Web of Science ®Google Scholar
• Shayman JA. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 2010;35:613-20
   PubMed Web of Science ®Google Scholar
• Lukina E, Watman N, Arreauin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment – 2 year results if a phase 2 study. Blood 2010;116:4095-8
   PubMed Web of Science ®Google Scholar
• Weinreb NJ. Oral small molecule therapy for lysosomal storage diseases. Pediatr Endocrinol Rev 2013;11(Suppl 1):77-90
   PubMedGoogle Scholar
• Piran S, Amato D. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment. J Inherit Metab Dis 2010;33:271-9
   PubMedGoogle Scholar
• Khan A, Hangartner T, Weinreb NJ, et al. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease : a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. J Bone Miner Res 2012;27:1839-48
   PubMed Web of Science ®Google Scholar
• Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004;104:1253-7
   PubMed Web of Science ®Google Scholar
• Saranjam HR, Sidransky E, Levine WZ, et al. Mandibular and dental manifestations of Gaucher disease. Oral Dis 2012;18:421-9
   PubMedGoogle Scholar
• Kumar NS, John RR, Rethish E. Relatively rare entity of avascular necrosis of maxillary bone caused by Gaucher's disease – a case report. J Oral Maxillofac Surg 2012;70:2590-5
   PubMedGoogle Scholar
• Lebel E, Ioscovich A, Itzchaki M, et al. Hip arthroplasty in patients with Gaucher disease. Blood Cells Mol Dis 2011;46:60-5
   PubMedGoogle Scholar
• Johannson HR, Zywiel MG, Marker DR, et al. Osteonecrosis is not a predictor of poor outcomes in primary total hip arthroplasty: a systematic literature review. Int Orthop 2011;35:465-73
   PubMedGoogle Scholar
• Lebel E, Elstein D, Peleg A, et al. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement. Am J Clin Pathol 2013;140:91-6
   PubMedGoogle Scholar
• Lebel E, Elstein D, Zimran A, Itzchaki M. Cementless total hip arthroplasties in Gaucher disease: long-term follow-up. Am J Orthop (Belle Mead NJ) 2009;38:130-2
   PubMedGoogle Scholar
• Donaldson J, Khan WS, Tailor H, et al. Gaucher disease: outcome following total hip replacements and effect of enzyme replacement therapy in a cohort of UK patients. Hip Int 2011;21:665-71
   PubMedGoogle Scholar
• Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocrin Rev 1996;17:333-68
   PubMed Web of Science ®Google Scholar
• Scheven BA, Milne JS, Robins SP. A sequential culture to study osteoclast differentiation from nonadherent procine bone marrow cells. In Vito Cell dev Biol Anim 1998;34:568-77
   PubMed Web of Science ®Google Scholar
• Edwards JR, Mundy GR. Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 2011;7:235-43
   Google Scholar
• Eyre DR. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand Suppl 1995;266:166-70
   PubMedGoogle Scholar
• Rosen HN, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers of low coeffeicient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-3
   PubMed Web of Science ®Google Scholar
• Rosenberg N, Rosenberg O, Soudry M. Osteoblasts in bone physiology-mini review. Rambam Maimonides Med J 2012;30:e0013
   Google Scholar
• Garnero P. Bone markers in osteoporosis. Curr Osteoporos Rep 2009;7:84-90
   PubMedGoogle Scholar
• Giuffrida G, Cingari MR, Parrinello N, et al. Bone turnover markers in patients with type 1 Gaucher disease. Hematol Rep 2012;19:e21
   Google Scholar
• Van Dussen L, Lips P, Everts VE, et al. Markers of bone turnover in Gaucher disease: remodeling the evolution of bone disease. J Clin Endocrinol Metab 2011;96:2194-205
   PubMedGoogle Scholar
• Drugan C, Jebeleanu G, Grigirescu-Sido P, et al. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type q Gaucher disease. Blood Cells Mol Dis 2002;28:13-20
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Mankin Dambrosia JM, et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 2002;28:288-96
   PubMed Web of Science ®Google Scholar
• Ciana G, Martini C, Leopaldi A, et al. Bone marker alterations in patients with type 1 Gaucher disease. Cacif Tissue Int 2003;72:185-9
   PubMed Web of Science ®Google Scholar
• Ciana G, Addobbati R, Tamaro G, et al. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 2005;28:723-32
   PubMed Web of Science ®Google Scholar
• Mikosch P, Reed M, Baker R, et al. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. Calcif Tissue Int 2008;83:43-54
   PubMedGoogle Scholar
• Mistry PK, Liu J, Yang M, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci 2010;107:19473-8
   PubMed Web of Science ®Google Scholar
• Reed M, Baker RJ, Mehta AB, Hughes DA. Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease. Blood Cells Mol Dis 2013;51:185-94
   PubMedGoogle Scholar
• Magal I, Lebel E, Altarescu G, et al. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. Br J Haematol 2006;133:93-7
   PubMedGoogle Scholar
• Mucci JM, Suqueli Garcia F, de Francesco PN, et al. Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease. Gene 2013;532:186-91
   PubMedGoogle Scholar
• Moran MT, Schefield JP, Hayman AR, et al. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclast cathepsins. Blood 2000;96:1969-78
   PubMed Web of Science ®Google Scholar
• Allen MJ, Myer BJ, Khoker AM, et al. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. Quart J Med 1997;90:19-25
   Google Scholar
• Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated plasma levels of M-CSF, CD-14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 1997;23:201-12
   PubMed Web of Science ®Google Scholar
• Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Path 2004;122:359-69
   PubMed Web of Science ®Google Scholar
• Xu YH, Jia L, Quinn B, et al. Global gene expression profile progression in Gaucher disease mouse models. BMC Genomics 2011;12:20
   PubMedGoogle Scholar
• Rosenbloom BE, Weinreb NJ. Gaucher disease: a comprehensive review. Crit Rev Oncogen 2013;18:163-75
   PubMedGoogle Scholar
• Campeau PM, Rafei M, Boivin MN, et al. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 2009;114:3181-90
   PubMed Web of Science ®Google Scholar
• Lecourt S, Mouly E, Freida D, et al. A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients. PLoS One 2013;8:e69293
   Google Scholar
• Berrebi A, Malnick SD, Vorst EJ, Stein D. High incidence of factor XI deficiency in Gaucher's disease. Am J Hematol 1992;40:153
   PubMedGoogle Scholar
• Hollak CE, Levi M, Berends F, et al. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and be partly restored by enzyme supplementation therapy. Br J Haematol 1997;96:47-476
   Google Scholar
• Deghady A, Marzouk I, El-shayeb A, Wali Y. Coagulation abnormalities in type 1 Gaucher disease in children. Pediatr Hematol Oncol 2006;23:411-17
   PubMed Web of Science ®Google Scholar
• Mitrovic M, Antic D, Elezovic I, et al. Haemostatic abnormalities in treatment-naïve patients with type 1 Gaucher's disease. Platelets 2012;23:143-9
   PubMed Web of Science ®Google Scholar
• Mitrovic N, Sumarac Z, Antic D, et al. Markers of coagulation activation and enhanced fibinolysis in Gaucher type 1 patients: effects of enzyme replacement therapy. Blood Cells Mol Dis 2012;49:58-9
   PubMedGoogle Scholar
• Sherif EM, Tantawy AA, Adly AA, et al. D-dimer assay in Egyptian patient w with gaucher disease: correlation with bone and lung involvement. Blood Coagul Fibrinolysis 2011;22:176-84
   PubMedGoogle Scholar
• Shitrit D, Rudensky B, Zimran A, Elstein D. D-dimer assay in Gaucher disease: correlation with severity of bone and lung involvement. Am J Hematol 2003;73:236-9
   PubMed Web of Science ®Google Scholar
• Bratosin D, Tissier JP, Lapillonne H, et al. A cytometric study of the red blood cell in Gaucher disease reveals their abnormal shape that may be involved in increased erythrophagocytosis. Cytometry B Clin Cytom 2011;80:28-37
   PubMedGoogle Scholar
• Franco M, Collec E, Connes P, et al. Abnormal properties of red blood cells suggest a role in the pathophysiology of Gaucher disease. Blood 2013;121:546-55
   PubMedGoogle Scholar
• Weinreb NJ. Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opin Pharmacother 2008;9:1987-2000
   PubMed Web of Science ®Google Scholar
• Cox TM, Aerts JM, Belmatouq N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008;31:319-36
   PubMed Web of Science ®Google Scholar
• Itzchaki M, Lebel E, Dweck A, et al. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy. Acta Orthop Scand 2004;75:541-653
   Google Scholar
• Zanchetta MB, Diehl M, Buttazoni M, et al. Assessment of bone microarchitecture in postmenopausal women on long term bisphosphonate therapy with atypical fractures of the femur. J Bone Miner Res 2013. [ Epub ahead of print]
   PubMedGoogle Scholar
• Pavlova EV, Wang SZ, Archer J, et al. B cell lymphoma and myeloma in murine Gaucher's disease. J Pathol 2013;231:88-97
   PubMed Web of Science ®Google Scholar